Pharmaceutical compounds
    4.
    发明授权
    Pharmaceutical compounds 失效
    药物化合物

    公开(公告)号:US5410061A

    公开(公告)日:1995-04-25

    申请号:US962365

    申请日:1992-10-16

    CPC分类号: C07D401/12 C07D401/14

    摘要: A compound having pharmaceutical activity, of the formula ##STR1## in which A is hydrogen or --(CR.sup.1 R.sup.2).sub.x R.sup.3 where x is 0 or 1 to 4, R.sup.1 and R.sup.2 are each hydrogen or C.sub.1-4 alkyl and R.sup.3 is --CN, --COOH, tetrazolyl or --CONHSO.sub.2 R.sup.4 where R.sup.4 is optionally substituted phenyl, and ##STR2## where R.sup.5 and R.sup.6 are each hydrogen, C.sub.1-4 alkyl or --(CR.sup.1 R.sup.2).sub.x R.sup.3 where x, R.sup.1, R.sup.2 and R.sup.3 are as defined above, and R.sup.7 is hydrogen, C.sub.1-4 alkyl or --(CR.sup.1 R.sup.2).sub.x R.sup.3 where x is 1 to 4, and R.sup.1, R.sup.2 and R.sup.3 are as defined above;provided that when A is hydrogen at least one of R.sup.5, R.sup.6 and R.sup.7is --(CR.sup.1 R.sup.2).sub.x R.sup.3, and provided that when ##STR3## A is --(CR.sup.1 R.sup.2).sub.x R.sup.3 and x is 1 to 4 then R.sup.3 is --CONHSO.sub.2 R.sup.4 ;and salts and esters thereof.

    摘要翻译: 具有药物活性的化合物,其中A为氢或 - (CR 1 R 2)x R 3,其中x为0或1至4,R 1和R 2为氢或C 1-4烷基,R 3为 - CN,-COOH,四唑基或-CONHSO 2 R 4,其中R 4是任选取代的苯基,和其中R 5和R 6各自是氢,C 1-4烷基或 - (CR 1 R 2)x R 3,其中x,R 1,R 2 和R 3如上所定义,并且R 7是氢,C 1-4烷基或 - (CR 1 R 2)x R 3,其中x是1至4,并且R 1,R 2和R 3如上定义; 条件是当A为氢时,R 5,R 6和R 7中的至少一个为 - (CR 1 R 2)x R 3,并且条件是当A为 - (CR 1 R 2)x R 3且x为1至4时,R 3为-CONHSO 2 R 4; 及其盐和酯。

    Certain indole derivatives useful as leukotriene antagonists
    6.
    发明授权
    Certain indole derivatives useful as leukotriene antagonists 失效
    某些吲哚衍生物可用作白三烯拮抗剂

    公开(公告)号:US5281593A

    公开(公告)日:1994-01-25

    申请号:US54914

    申请日:1993-04-29

    摘要: A compound of the formula ##STR1## in which R.sup.1 is hydrogen, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, nitrile, optionally protected carboxy, optionally protected tetrazolyl, trihalomethyl, hydroxy-C.sub.1-4 alkyl, aldehydo, --CH.sub.2 Z, --CH.dbd.CH--Z or --CH.sub.2 CH.sub.2 Z where Z is optionally protected carboxy or optionally protected tetrazolyl; R.sup.2 is halo, nitrile, an optionally protected acid group or --CONR.sup.7 R.sup.8 where R.sup.7 and R.sup.8 are each hydrogen or C.sub.1-4 alkyl; R.sup.3 and R.sup.4 are each hydrogen, C.sub.1-4 alkyl, optionally substituted phenyl, or C.sub.1-4 alkyl substituted by --CONR.sup.7 R.sup.8 or an optionally protected acid group; R.sup.5 is ##STR2## where W is --CH.dbd.CH--, --CH.dbd.N--, --N.dbd.CH--, --O-- or --S--, R.sup.9 is hydrogen, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or trihalomethyl, and R.sup.10 is hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl or C.sub.1-4 alkyl-C.sub.3-6 cycloalkyl; R.sup.6 is hydrogen or C.sub.1-4 alkyl; X is --O--(CH.sub.2).sub.n CR.sup.11 R.sup.12, --CR.sup.11 R.sup.12 --, --CR.sup.11 R.sup.12.(CH.sub.2).sub.n.CR.sup.13 R.sup.14 -- or --CR.sup.11 .dbd.CR.sup.12 -- where R.sup.11, R.sup.12, R.sup.13 and R.sup.14 are each hydrogen or C.sub.1-4 alkyl, and n is 0, 1 or 2; and Y is --O--CR.sup.15 R.sup.16 --, --CR.sup.15 .dbd.CR.sup.16 -- or --CR.sup.15 R.sup.16.CR.sup.17 R.sup.18 -- where R.sup.15, R.sup.16, R.sup.17 and R.sup.18 are each hydrogen or C.sub. 1-4 alkyl; or a salt thereof. The compounds in unprotected form are active as leukotriene antagonists.

    摘要翻译: 其中R 1为氢,卤素,C 1-4烷基,C 1-4烷氧基,腈,任意保护的羧基,任意保护的四唑基,三卤代甲基,羟基-C 1-4烷基,醛,-CH 2 Z, -CH = CH-Z或-CH 2 CH 2 Z,其中Z为任选保护的羧基或任选保护的四唑基; R 2是卤素,腈,任意保护的酸基或-CONR 7 R 8,其中R 7和R 8各自是氢或C 1-4烷基; R 3和R 4各自为氢,C 1-4烷基,任选取代的苯基或被-CONR 7 R 8或任选保护的酸基取代的C 1-4烷基; R5是 其中W是-CH = CH-,-CH = N-,-N = CH-,-O-或-S-,R9是氢,卤素,C1-4烷基,C1- 4烷氧基或三卤甲基,R 10是氢,C 1-4烷基,C 2-6烯基,C 3-6环烷基或C 1-4烷基-C 3-6环烷基; R6是氢或C1-4烷基; X是-O-(CH 2)n CR 11 R 12,-CR 11 R 12 - , - CR 11 R 12。(CH 2)n CR 1 R 14 - 或-CR 11 = CR 12 - ,其中R 11,R 12,R 13和R 14各自是氢或C 1-4烷基,n是 0,1或2; 并且Y是-O-CR 15 R 16 - , - CR 15 = CR 16 - 或-CR 15 R 16 CR 17 R 18 - ,其中R 15,R 16,R 17和R 18各自是氢或C 1-4烷基; 或其盐。 未保护形式的化合物作为白三烯拮抗剂是活性的。